At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 137 enrolled
Drug / intervention
brivanib (active)drug
Likely dose
brivanib (active) 800 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase II Open Label Study of Brivanib (BMS582664), Administered Orally At A Dose of 800 mg Daily In Subjects With Unresectable, Locally Advanced or Metastatic Hepatocellular Carcinoma Who Have Received Either No Prior Systemic Therapy or One Prior Regimen of Angiogenesis Inhibitor Therapy
In Brief
A Phase 2 clinical trial evaluating brivanib (active) for Hepatocellular Carcinoma (HCC). Completed, enrolled 137 participants across 37 sites in 8 countries.
Detailed Summary
The purpose of this clinical research study is to learn if BMS-582664 can shrink or slow the growth of advanced liver cancer. The safety of this treatment will also be studied.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHepatocellular Carcinoma (HCC)
CountriesFrance, Hong Kong, Malaysia, Philippines, Singapore, South Korea, Taiwan, United States
Collaborators--
Timeline
Phase 2CompletedFinished
2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedJul 2006
Enrollment StartDec 2006
Primary CompletionApr 2010
TodayJul 2026
First PostedJul 21, 2006
Enrollment StartDec 31, 2006
Primary CompletionApr 30, 2010
TodayJul 2, 2026
Enrollment to primary: 3.3 yearsPosted 19.9 years ago
Interventions
brivanib (active)drug
Tablet, Oral, Brivanib 800 mg, once daily, until progression